INMD

InMode Ltd.

InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency (\'RF\') technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology.

InMode Ltd. (INMD) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Growth (D+). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
B
Factor Score 3.3 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
B-
Factor Score 3.0 / 5.0
Momentum
B-
Factor Score 2.9 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 11.3
EV / EBITDA 4.0
Rev Growth YoY -0.0%
Gross Margin 76.5%
Price Return 3M -9.7%
Price Return 12M -6.0%
Catalyst Signal 0.00
Market Cap $790.1M
TTM Revenue $374.6M
Price / Sales 2.1
ROE 12.3%

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 B (3.3) D+ (1.8) B- (3.0) B- (2.9) C+ (2.6) C+ (2.7)
2026-11-05 B (3.3) D+ (1.8) B- (3.0) B- (2.9) C+ (2.7) C+ (2.7)
2026-10-29 B (3.3) D+ (1.7) B- (3.0) C+ (2.6) C+ (2.7) C+ (2.6)
2026-10-22 B (3.3) D+ (1.8) B- (3.0) C+ (2.5) C+ (2.6) C+ (2.6)
2026-10-15 B (3.3) D+ (1.8) B- (3.0) C+ (2.6) C+ (2.6) C+ (2.7)
Page 1 of 4